The DOI matches its Crossref record, with a small difference in title or year; 27 of the 27 references it cites were found in a registry or an index.
Sodium Zirconium Cyclosilicate among Individuals with Hyperkalemia: A 12-Month Phase 3 Study
Open accessAbstract
Background and objectives: Oral sodium zirconium cyclosilicate (formerly ZS-9) binds and removes potassium via the gastrointestinal tract. Sodium zirconium cyclosilicate–associated restoration and maintenance of normokalemia and adverse events were evaluated in a two-part, open label, phase 3 trial. Design, setting, participants, & measurements: In the correction phase, adult outpatients with plasma potassium ≥5.1 mmol/L (i-STAT Point-of-Care) received sodium zirconium cyclosilicate 10 g three times daily for 24–72 hours until normokalemic (potassium =3.5–5.0 mmol/L). Qualifying participants entered the ≤12-month maintenance phase and received sodium zirconium cyclosilicate 5 g once daily titrated to maintain normokalemia without dietary or medication restrictions. Prespecified primary end points were restoration of normal serum potassium values (3.5–5.0 mmol/L) during the correction phase and maintenance of serum potassium ≤5.1 mmol/L during the maintenance phase. Adverse events were assessed throughout. Results: Of 751 participants, 746 (99%) achieved normokalemia during the correction phase (mean serum potassium =4.8 mmol/L; 95% confidence interval, 4.7 to 4.8) and entered the maintenance phase; 466 (63%) participants completed the 12-month trial. Participants were predominantly white, men, and age ≥65 years old; 74% had an eGFR<60 ml/min per 1.73 m 2 , and 65% used renin-angiotensin-aldosterone system inhibitors. Mean time on sodium zirconium cyclosilicate was 286 days. Mean daily sodium zirconium cyclosilicate dose was 7.2 g (SD=2.6). Over months 3–12, mean serum potassium was 4.7 mmol/L (95% confidence interval, 4.6 to 4.7); mean serum potassium values ≤5.1 and ≤5.5 mmol/L were achieved by 88% and 99% of participants, respectively. Of 483 renin-angiotensin-aldosterone system inhibitor users at baseline, 87% continued or had their dose increased; 11% discontinued. Among 263 renin-angiotensin-aldosterone system inhibitor–naïve participants, 14% initiated renin-angiotensin-aldosterone system inhibitor therapy. Overall, 489 (66%) participants experienced adverse events during the maintenance phase, and 22% experienced a serious adverse event. Of eight (1%) deaths, none were considered related to sodium zirconium cyclosilicate. Nine (1%) and 34 (5%) participants experienced serum potassium <3.0 and 3.0–3.4 mmol/L, respectively. Conclusions: After achieving normokalemia, individualized once daily sodium zirconium cyclosilicate was associated with maintenance of normokalemia without substantial renin-angiotensin-aldosterone system inhibitor changes for ≤12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, clinical outcomes were not evaluated;”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ef fi cacy and safety data beyond 1 year of treatment are not available;”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment with potassium binders, such as patiromer or sodium zirconium cyclosilicate, where each has been used to treat hyperkalemia associated with RAS blockade therapy for up to 12 months. 83,84”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both studies demonstrated the effectiveness of achieving normokalemia and that treatment with RAS blockade agents can be continued without treatment-related serious adverse effects.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [84]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Weir, M. R., Bakris, G. L., Bushinsky, D. A., Mayo, M. R., Garza, D., Stasiv, Y., Wittes, J. T., Christ‐Schmidt, H., Berman, L., & Pitt, B. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1410853 · Cited by 683
The Frequency of Hyperkalemia and Its Significance in Chronic Kidney Disease
Einhorn, L. M., Zhan, M., Hsu, V. D., Walker, L. D., Moen, M. F., Seliger, S. L., Weir, M. R., & Fink, J. C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.132 · Cited by 655
Sodium Zirconium Cyclosilicate in Hyperkalemia
Packham, D., Rasmussen, H. S., Lavin, P. T., El-Shahawy, M. A., Roger, S. D., Block, G. A., Qunibi, W. Y., Pérgola, P. E., & Singh, B. P. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411487 · Cited by 505
Self-citationAvosentan for Overt Diabetic Nephropathy
Mann, J. F. E., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S., Littke, T., & Viberti, G. C. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009060593 · Cited by 501
Kosiborod, M., Rasmussen, H. S., Lavin, P. T., Qunibi, W. Y., Spinowitz, B., Packham, D., Roger, S. D., Yang, A., Lerma, E. V., & Singh, B. P. (2014) · JAMA · doi:10.1001/jama.2014.15688 · Cited by 414
Self-citationHarel, Z., Harel, S., Shah, P. S., Wald, R., Perl, J. M., & Bell, C. M. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.08.016 · Cited by 324
Ion-Exchange Resins for the Treatment of Hyperkalemia
Sterns, R. H., Rojas, M. P. L., Bernstein, P. L., & Chennupati, S. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010079 · Cited by 303
Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function
Luo, J., Brunelli, S. M., Jensen, D. E., & Yang, A. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01730215 · Cited by 288
Predictors of Hyperkalemia and Death in Patients With Cardiac and Renal Disease
Jain, N., Kotla, S. K., Little, B. B., Weideman, R. A., Brilakis, E. S., Reilly, R. F., & Banerjee, S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.01.367 · Cited by 219
McGill, J. B., Sloan, L. A., Newman, J., Patel, S. D., Sauce, C., von Eynatten, M., & Woerle, H. (2012) · Diabetes Care · doi:10.2337/dc12-0706 · Cited by 203
Cited by
Sorted by citations
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.003 · Cited by 1,452
European Resuscitation Council Guidelines 2021: Cardiac arrest in special circumstances
Lott, C., Truhlář, A., Alfonzo, A. V. M., Barelli, A., Salvado, V. G., Hinkelbein, J., Nolan, J. P., Paal, P., Perkins, G. D., Thies, K., et al. (2021) · Resuscitation · doi:10.1016/j.resuscitation.2021.02.011 · Cited by 839
Clase, C. M., Carrero, J.-J., Ellison, D. H., Grams, M. E., Hemmelgarn, B. R., Jardine, M. J., Kovesdy, C. P., Kline, G. A., Lindner, G., Obrador, G. T., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.018 · Cited by 498
Self-citationJones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 424
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001356 · Cited by 335
Abnormalities of Potassium in Heart Failure
Ferreira, J. P., Butler, J., Rossignol, P., Pitt, B., Anker, S. D., Kosiborod, M., Lund, L. H., Bakris, G. L., Weir, M. R., & Zannad, F. M. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.021 · Cited by 208
Self-citationClinical Management of Hyperkalemia
Palmer, B. F., Carrero, J. J., Clegg, D. J., Colbert, G. B., Emmett, M., Fishbane, S. N., Hain, D. J., Lerma, E. V., Onuigbo, M. A. C., Rastogi, A., et al. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.06.014 · Cited by 204
Self-citationPalmer, B. F. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.05.019 · Cited by 117
Roger, S. D., Spinowitz, B., Lerma, E. V., Singh, B. P., Packham, D., Al‐Shurbaji, A., & Kosiborod, M. (2019) · American Journal of Nephrology · doi:10.1159/000504078 · Cited by 89
Self-citationPeacock, W. F., Rafique, Z., Vishnevskii, K. A., Michelson, E. A., Vishneva, Е. A., Zvereva, T. N., Nahra, R., Dao, L., & Miller, J. B. (2020) · Academic Emergency Medicine · doi:10.1111/acem.13954 · Cited by 85
Impact of Dietary Potassium Restrictions in CKD on Clinical Outcomes: Benefits of a Plant-Based Diet
Clegg, D. J., Headley, S., & Germain, M. J. (2020) · Kidney Medicine · doi:10.1016/j.xkme.2020.04.007 · Cited by 79
Zannad, F. M., Hsu, B., Maeda, Y., Shin, S. K., Vishneva, E. M., Rensfeldt, M., Eklund, S., & Zhao, J. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12561 · Cited by 77
Self-citationHougen, I., Leon, S. J., Whitlock, R. H., Rigatto, C., Komenda, P. V. J., Bohm, C. J., & Tangri, N. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.02.038 · Cited by 70
Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management
Hundemer, G. L., & Sood, M. M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105835 · Cited by 67
Roger, S. D., Lavin, P. T., Lerma, E. V., McCullough, P. A., Butler, J., Spinowitz, B., von Haehling, S., Kosiborod, M., Zhao, J., Fishbane, S. N., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz285 · Cited by 65
Self-citationCurrent Management of Hyperkalemia in Patients on Dialysis
Bansal, S., & Pérgola, P. E. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.02.1028 · Cited by 66
Kosiborod, M., Cherney, D. Z. I., Desai, A. S., Testani, J. M., Verma, S., Chinnakondepalli, K., Dolling, D. I., Patel, S., Dahl, M., Eudicone, J. M., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.014 · Cited by 56
Self-citationHyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies
Valdivielso, J. M., Balafa, O. C., Ekart, R., Ferro, C. J., Mallamaci, F., Mark, P. B., Rossignol, P., Sarafidis, P. A., Vecchio, L. D., & Ortíz, A. (2021) · Drugs · doi:10.1007/s40265-021-01555-5 · Cited by 57
Kreislaufstillstand unter besonderen Umständen
Lott, C., Truhlář, A., Alfonzo, A., Barelli, A., Salvado, V. G., Hinkelbein, J., Nolan, J. P., Paal, P., Perkins, G. D., Thies, K., et al. (2021) · Notfall + Rettungsmedizin · doi:10.1007/s10049-021-00891-z · Cited by 52
Hyperkalemia: Prevalence, Predictors and Emerging Treatments
Larivée, N., Michaud, J. B., More, K. M., Wilson, J.-A. S., & Tennankore, K. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00289-z · Cited by 51
Potassium homeostasis – Physiology and pharmacology in a clinical context
Kettritz, R., & Loffing, J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108489 · Cited by 54
Morales, E., Cravedi, P., & Manrique, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.653634 · Cited by 48
Hyperkalemia in patients with chronic renal failure
Seliger, S. L. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz231 · Cited by 46
Hyperkalemia treatment standard
Palmer, B. F., & Clegg, D. J. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae056 · Cited by 43
Reappraisal on pharmacological and mechanical treatments of heart failure
Liang, B., Zhao, Y.-X., Zhang, X., Liao, H.-L., & Gu, N. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01024-5 · Cited by 39
Gaddy, A. R., Elrggal, M. E., Madariaga, H. M., Kelly, A., Lerma, E. V., & Colbert, G. B. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101848 · Cited by 40
Self-citationSussman, E. J., Singh, B. P., Clegg, D. J., Palmer, B. F., & Kalantar‐Zadeh, K. (2020) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2020.01.022 · Cited by 34
Self-citationLoutradis, C., Price, A. M., Ferro, C. J., & Sarafidis, P. A. (2021) · Journal of Human Hypertension · doi:10.1038/s41371-021-00504-9 · Cited by 31
Weinstein, J. J., Girard, L., Lepage, S., McKelvie, R. S., & Tennankore, K. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.210831 · Cited by 30
Zhuo, M., Kim, S. C., Patorno, E., & Paik, J. M. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.04.003 · Cited by 30
Nicola, L. D., Ferraro, P. M., Montagnani, A., Pontremoli, R., Dentali, F., & Sesti, G. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-023-03427-0 · Cited by 34
Borrelli, S., Nicola, L. D., Minutolo, R., Conte, G., Chiodini, P., Cupisti, A., Santoro, D., Calabrese, V., Giannese, D., Garofalo, C., et al. (2021) · Nutrients · doi:10.3390/nu13030942 · Cited by 32
Roger, S. D., Spinowitz, B., Lerma, E. V., Fishbane, S. N., Ash, S. R., Martins, J. G., Quinn, C. M., & Packham, D. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa158 · Cited by 27
Self-citationZhang, Y., Xu, R., Wang, F., Liu, Y., Xu, J., Zhao, N., Cheng, F., Long, L., Jia, J., & Lin, S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07134-2 · Cited by 27
Sidhu, K., Sanjanwala, R., & Zieroth, S. R. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000709 · Cited by 27
Pharmacologic Treatment of Chronic Hyperkalemia in Patients with Chronic Kidney Disease
Kim, G. (2019) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2019.17.1.1 · Cited by 27
Hyperkalemia in heart failure: Foe or friend?
Rakisheva, A., Marketou, M. E., Сергеевна, К. А., Troyanova‐Shchutskaia, T., & Vardas, P. E. (2020) · Clinical Cardiology · doi:10.1002/clc.23392 · Cited by 29
Agiro, A., An, A., Cook, E. E., Mu, F., Chen, J., Desai, P., Oluwatosin, Y., & Pollack, C. V. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02518-w · Cited by 26
Rastogi, A., Pollack, C. V., Sánchez-Lázaro, I. J., Lesén, E., Arnold, M., Franzén, S., Allum, A. M., Hernández, I., Murohara, T., & Kanda, E. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae083 · Cited by 24
New Treatment Options for Hyperkalemia in Patients with Chronic Kidney Disease
Esposito, P. B., Conti, N. E., Falqui, V., Cipriani, L., Picciotto, D., Costigliolo, F., Garibotto, G., Saio, M., & Viazzi, F. C. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082337 · Cited by 23
Albakr, R. B., Sridhar, V. S., & Cherney, D. Z. I. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.04.015 · Cited by 25
Population Epidemiology of Hyperkalemia: Cardiac and Kidney Long-term Health Outcomes
Mclean, A., Nath, M., & Sawhney, S. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.07.008 · Cited by 22
Documento de consenso sobre el abordaje de la hiperpotasemia
Ortíz, A., del Arco, C., Fernández‐García, J. C., Cerezo, J. G., Ochoa, R. I., Núñez, J. E., Gutiérrez, F. P., & Navarro‐González, J. F. (2023) · Nefrología · doi:10.1016/j.nefro.2023.05.004 · Cited by 24
Pivotal clinical trials, meta-analyses and current guidelines in the treatment of hyperkalemia
Bianchi, S., & Regolisti, G. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz213 · Cited by 22
Kim, K., Fagerström, J., Chen, G., Lagunova, Z., Furuland, H., & McEwan, P. C. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02903-7 · Cited by 20
Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting
Fishbane, S. N., Charytan, D. M., Chertow, G. M., Ford, M. L., Kovesdy, C. P., Pérgola, P. E., Pollock, C. A., & Spinowitz, B. (2021) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2021.06.003 · Cited by 19
Self-citationChronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers
Borrelli, S., Matarazzo, I., Lembo, E., Peccarino, L., Annoiato, C., Scognamiglio, M., Foderini, A., Ruotolo, C., Franculli, A., Capozzi, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126378 · Cited by 22
Sharma, A. K., Alvarez, P. J., Woods, S. D., Fogli, J., & Dai, D. (2021) · Journal of Pharmaceutical Health Services Research · doi:10.1093/jphsr/rmaa004 · Cited by 18
Dai, D., Alvarez, P. J., & Woods, S. D. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s313857 · Cited by 17
Hyperkalemia in heart failure: current treatment and new therapeutic perspectives
Minà, C., Ajello, L., Gesaro, G. D., Falletta, C., & Clemenza, F. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.02.8 · Cited by 17
An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia
Takkar, C., Nassar, T. I., & Qunibi, W. Y. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1810234 · Cited by 17
Kashihara, N., Yamasaki, Y., Osonoi, T., Harada, H., Shibagaki, Y., Zhao, J., Kim, H., Yajima, T., & Sarai, N. (2020) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01972-y · Cited by 17
Self-citationGórriz, J. L., D’Marco, L., Pastor-González, A., Molina, P., González-Rico, M., Puchades, M. J., Sanchís, I., Escudero, V., Estañ-Capell, N., de la Espriella, R., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab003 · Cited by 17
Cherney, D. Z. I., Bell, A., Girard, L., McFarlane, P. A., MOIST, L. M., Nessim, S. J., Soroka, S. D., Stafford, S. G., Steele, A., Tangri, N., et al. (2023) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581221150556 · Cited by 18
Managing Hyperkalemia in the Modern Era: A Case-Based Approach
Massicotte‐Azarniouch, D., Canney, M., Sood, M. M., & Hundemer, G. L. (2023) · Kidney International Reports · doi:10.1016/j.ekir.2023.04.016 · Cited by 17
Ni, Z., Xu, X., Xu, X., Bian, X., Zhou, Z., Yang, J., Luo, Q., Chen, C., Chen, C., Sun, X., et al. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.04.014 · Cited by 16
Self-citationConsensus statement on the management of hyperkalaemia—An Asia–Pacific perspective
Yap, D. Y. H., Ronald, C. W., Wong, E. C. K., Tsui, M. S. H., Yu, E. Y. T., Yu, V., Szeto, C., Pang, W., Tse, H., Siu, D. C. W., et al. (2024) · Nephrology · doi:10.1111/nep.14281 · Cited by 16
Management of hyperkalemia: A focus on kidney transplant recipients
Almalki, B. A., Cunningham, K. C., Kapugi, M., Kane, C., & Agrawal, A. (2021) · Transplantation Reviews · doi:10.1016/j.trre.2021.100611 · Cited by 15
Lima, A. O. D. L., Castro, Ó. D., Romero-Requena, J. M., Díaz-Guerra, M. D. L. R. G., Pineda, V. A., Diaz, M., Ascanio, M., Darbà, J., & Cruzado, J. M. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab076 · Cited by 16
Lisi, F., Parisi, G., Gioia, M. I., Amato, L., Bellino, M. C., Grande, D., Massari, F., Caldarola, P., Ciccone, M. M., & Iacoviello, M. (2020) · Cardiorenal Medicine · doi:10.1159/000505286 · Cited by 16
Pollack, C. V., Agiro, A., Mu, F., Cook, E. E., Wirtz, E. L., Young, J. A., Betts, K. A., & Brahmbhatt, Y. G. (2022) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2023.2161514 · Cited by 15
Österreichischer Blutdruckkonsens 2019
Hypertensiologie, Ö. G. F., Weber, T., Atherosklerosegesellschaft, Ö., Gesellschaft, Ö. D., Angiologie, Ö. G. F. I., Nephrologie, Ö. G. F., Gesellschaft, Ö. K., Neurologie, Ö. G. F., Schlaganfall-Gesellschaft, Ö., Allgemeinmedizin, Ö. G. F., et al. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-01565-0 · Cited by 15
Fernández-Prado, R., Villalvazo, P., Avello, A., de Rivera, M. G., Aguirre, M., Carrasco-Muñoz, C. G., Fernández‐Fernández, B., Martín-Cleary, C., Carriazo, S. M., Sánchez-Niño, M. D., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114197 · Cited by 14
AlSahow, A., AbdulShafy, M., Al-Ghamdi, S. M. G., AlJoburi, H., Almogbel, O., Al‐Rowaie, F., Attallah, N. M., Bader, F. M., Hussein, H., Hassan, M. H., et al. (2023) · Journal of Clinical Hypertension · doi:10.1111/jch.14633 · Cited by 14
Rossignol, P., & Pitt, B. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad090 · Cited by 14
Kashihara, N., Nishio, T., Osonoi, T., Saka, Y., Imasawa, T., Ohtake, T., Mizuno, H., Shibagaki, Y., Kim, H., Yajima, T., et al. (2020) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-01937-1 · Cited by 14
Hasara, S., Dubey, J., Amatea, J., & Finnigan, N. A. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.12.043 · Cited by 13
Rastogi, A., Chertow, G. M., Collins, A. K., Kelepouris, E., Kotzker, W. R., Middleton, J. P., Rajpal, M., & Roy‐Chaudhury, P. (2024) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2024.08.003 · Cited by 13
Fishbane, S. N., Ford, M. L., Fukagawa, M., McCafferty, K., Rastogi, A., Spinowitz, B., Staroselskiy, K., Vishnevskii, K. A., Lisovskaja, V., Al‐Shurbaji, A., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-021-02569-7 · Cited by 13
Self-citationManagement of Hypertension in Diabetic Kidney Disease
Colbert, G. B., Elrggal, M. E., Gaddy, A. R., Madariaga, H. M., & Lerma, E. V. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12216868 · Cited by 11
Self-citationHyperkalemia: Pharmacotherapies and Clinical Considerations
Sinnathamby, E. S., Banh, K., Barham, W. T., Hernandez, T. D., Witt, A. J. D., Wenger, D. M., Klapper, V. G., McGregor, D., Paladini, A., Ahmadzadeh, S., et al. (2024) · Cureus · doi:10.7759/cureus.52994 · Cited by 12
Ash, S. R., BATLLE, D. C., Kendrick, J., Oluwatosin, Y. E., Pottorf, W. J., Brahmbhatt, Y. G., Guerrieri, E., & Fried, L. F. (2022) · The Nephron journals/Nephron journals · doi:10.1159/000523911 · Cited by 12
Hyperkalemia in chronic kidney disease: a focus on potassium lowering pharmacotherapy
Sampani, E., Theodorakopoulou, M., Iatridi, F., & Sarafidis, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2245756 · Cited by 11
Kreitzer, N. P., Albert, N. M., Amin, A., Beavers, C. J., Becker, R. C., Fonarow, G. C., Gibler, W. B., Kwon, K. W., Mentz, R. J., Palmer, B. F., et al. (2025) · Cardiorenal Medicine · doi:10.1159/000543385 · Cited by 14
Consensus document on the management of hyperkalemia
Ortíz, A., del Arco, C., Fernández‐García, J. C., Cerezo, J. G., Ochoa, R. I., Núñez, J. E., Gutiérrez, F. P., & Navarro‐González, J. F. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.12.002 · Cited by 14
Rossignol, P., Silva‐Cardoso, J., Kosiborod, M., Brandenburg, V. M., Cleland, J. G. F., Hadimeri, H., Hullin, R., Mäkelä, S., Mörtl, D., Paoletti, E., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106277 · Cited by 12
Self-citationThe randomized DIALIZE-Outcomes trial evaluated sodium zirconium cyclosilicate in hemodialysis
Fishbane, S. N., Dember, L. M., Jadoul, M. Y., Kovesdy, C. P., Guzman, N. J., Kordzakhia, G., Lisovskaja, V., Sekar, P., Wessman, P., Al‐Shurbaji, A., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.06.016 · Cited by 10
Self-citationBridgeman, M. B., Shah, M., & Foote, E. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz223 · Cited by 10
Johnson, M., Morrison, F. J. R., McMahon, G. M., Su, M., & Turchin, A. (2023) · American Heart Journal · doi:10.1016/j.ahj.2023.01.002 · Cited by 10
Prevention of Chronic Kidney Disease and Its Complications in Older Adults
Tungsanga, S., & Bello, A. K. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01128-7 · Cited by 9
Dwyer, J. P., Agiro, A., Desai, P., & Oluwatosin, Y. E. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02631-w · Cited by 9
Individualized Diets in Patients with Kidney Disease and Kidney Transplants: A Narrative Review
Hu, L., Borelli, G., Gessaroli, E., Ruotolo, C., Bin, S., Papalia, G., Patella, G., Liberti, M. E., Baraldi, O., Zaza, G., et al. (2025) · Life · doi:10.3390/life15060896 · Cited by 9
Inpatient management and post-discharge outcomes of hyperkalemia
Davis, J. R., Israni, R., Mu, F., Cook, E. E., Szerlip, H. M., Uwaifo, G. I., Fonseca, V. A., & Betts, K. A. (2021) · Hospital Practice · doi:10.1080/21548331.2021.1925554 · Cited by 8
Hyperkalaemia in Heart Failure
Ismail, U., Sidhu, K., & Zieroth, S. R. (2021) · Cardiac failure review · doi:10.15420/cfr.2020.29 · Cited by 8
Prevalence of Metabolic Acidosis Among Patients with Chronic Kidney Disease and Hyperkalemia
Cook, E. E., Davis, J. R., Israni, R., Mu, F., Betts, K. A., Anzalone, D. A., Yin, L., Szerlip, H. M., Uwaifo, G. I., Fonseca, V. A., et al. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01886-5 · Cited by 8
Wheeler, D. C., Søndergaard, H., Gwynn, C. W., Hedman, K., Hedberg, J., Allum, A. M., Chung, H.-L., Någård, M. B., Stjernlöf, G., Wittbrodt, E. T., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-074954 · Cited by 7
Aldosterone and Potassium in Heart Failure: Overcoming This Major Impediment in Clinical Practice
Khan, L. A., Jamil, A., Greene, S. J., Khan, M. S., & Butler, J. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.09 · Cited by 7
Self-citationPotassium binding for conservative and preservative management of chronic kidney disease
Clegg, D. J., & Palmer, B. F. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000564 · Cited by 7
Fishbane, S. N., Jadoul, M. Y., Dember, L. M., Kovesdy, C. P., Al‐Shurbaji, A., Lisovskaja, V., Sekar, P., Katona, B. G., Guzman, N. J., & Herzog, C. A. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-071309 · Cited by 7
Self-citationGray, J. P., Kim, J. R., & Ray, S. D. (2019) · Side effects of drugs annual · doi:10.1016/bs.seda.2019.07.010 · Cited by 7
Agiro, A., Mu, F., Cook, E. E., Greatsinger, A., Chen, J., Zhao, A., Louden, E. M., Colman, E., Desai, P., & Chertow, G. M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035256 · Cited by 7
Agiro, A., Greatsinger, A., Mu, F., Cook, E. E., Chen, J., Sundar, M., Zhao, A., Colman, E., & Malhotra, A. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03254-z · Cited by 6
Yao, L., Xing, X., Li, Y., Zhang, F., Li, P., Liang, X., & Wang, P. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03530-4 · Cited by 6
Hida, Y., Imamura, T., & Kinugawa, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185971 · Cited by 6
Khandelwal, P., Shah, S., McAlister, L., Cleghorn, S., King, L., & Shroff, R. C. (2023) · Pediatric Nephrology · doi:10.1007/s00467-023-06176-6 · Cited by 6
Fecal ammonium in mice with CKD: gastrointestinal sequestration by sodium zirconium cyclosilicate
Marmol-Mosquera, F., Badaruddin, M., Baig, A., Ye, M., Wysocki, J. A., Tahaei, E., Welling, P. A., Bamberg, K., & BATLLE, D. C. (2023) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00312.2022 · Cited by 6
Chapman, A. B., & Gunning, S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.014845 · Cited by 6
Metadata
- Authors
- Spinowitz, B. S., Fishbane, S., Pergola, P. E., Roger, S. D., Lerma, E. V., Butler, J., von Haehling, S., Adler, S. H., Zhao, J., Singh, B., Lavin, P. T., McCullough, P. A., Kosiborod, M., Packham, D. K., & on behalf of the ZS-005 Study Investigators
- Affiliations
- New York Hospital Queens (US)
- Hofstra University (US)
- Renal Associates PA, San Antonio, Texas;
- Gosford Hospital (AU)
- University of Illinois Chicago (US)
- University of Mississippi (US)
- Universitätsmedizin Göttingen (DE)
- AstraZeneca (United States) (US)
- University of California, Irvine (US)
- Boston Biostatistics Research Foundation, Framingham, Massachusetts;
- Baylor University Medical Center (US)
- The George Institute for Global Health (AU)
- The University of Melbourne (AU)
- Corresponding author
- Spinowitz, Bruce S.
- ORCID
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2019-05-20
- Volume
- 14
- Issue
- 6
- Pages
- 798-809
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC6556727
- OpenAlex
- W2946005791
- Cited by
- 198
- References
- 27
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 33 · 2023: 35 · 2022: 17 · 2021: 28 · 2020: 24 · 2019: 17
- FWCI
- 15.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Nephrology › Potassium and Related Disorders
- Health Sciences › Medicine › Nephrology › Parathyroid Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- hyperkalemia, potassium homeostasis, renin-angiotensin-aldosterone system inhibitors, adverse events, hypokalemia, serum potassium, maintenance therapy, drug safety, renal potassium excretion, sodium zirconium cyclosilicate
- MeSH terms
- Adult, Aged, Humans, Hyperkalemia, Male, Potassium, Renin-Angiotensin System, Silicates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
